Notes archive.
TCFC Finance corrects FY26 audited results, fixes record date for capital reduction
The nano-cap's revised filing confirms the net loss but adds administrative detail on a previously approved capital reduction.
IdeaForge gets a second credit rating. It changes little.
India Ratings assigned a BBB/Stable long-term issuer rating, confirming a credit profile already established by CRISIL and the company's own filings.
Olectra files its FY26 call transcript. It adds nothing new.
A routine filing of the June 1 earnings call transcript. The numbers and commentary were already public.
Transvoy promoter sells 4.6% of the company in a single day
Dipti Ravindra Joshi cut her stake by 4.6 percentage points in a nano-cap where that size of trade is a big slice of the float.
Alembic lands generic Haldol approval, but the US market is tiny
Final USFDA clearance for Haloperidol Tablets adds to a 240-product pipeline. The market it addresses is less than 3% of Alembic's revenue.
Confidence Petroleum promoter pledges 7.86% of equity for working capital
A single transaction lifted total promoter group encumbrance from under 1% to nearly 9% of the company's equity.
Bajaj Electricals says it's now in cables. That's about all it said.
The company has announced a new product line under its Lighting Solutions segment, but provided no investment amount, revenue targets, or timeline.
HCC lands ₹127 cr Bhutan hydro contract, adds to Bhutan pipeline
The Wangchhu project win is small at 2% of market cap but continues HCC's 30-year run in Bhutanese hydropower.
Glenmark's transcript adds detail to its margin cut and Envafolimab delay
The Q4 call transcript documents the guidance downgrade to 21-22% EBITDA margin and the push of a key launch to FY28, but adds little new information beyond the concall summary.
Lupin lands sole US interchangeable biosimilar for Roche's Lucentis
The FDA approval for Ranluspec makes Lupin's product the only interchangeable ranibizumab biosimilar in the United States, a key regulatory distinction in the crowded eye-drug market.
Novelix is selling 5% of itself to 18 investors for ₹6.84 cr.
The board approved a preferential issue at ₹57 a share, a ₹47 premium to face value. Shareholder approval is needed by July 2026.
Ambo Agritec's FY26 results are now official. The filing adds nothing new.
The board approved the audited numbers and rehired the internal auditor. It's a routine compliance step during the reporting season.
DMR Engineering lands ₹2.59 cr Bhutan hydro mandate, a quarter of annual revenue
The nine-month consultancy contract for a 1,125 MW project is material for a nano-cap with ₹10.3 crore in annual sales.
Promoter Galla moves 14% of Enbee's equity to another group entity
Amarr Narendra Galla's personal stake fell from 24.45% to 10.25% in a single inter-se transfer within the promoter group.
NTPC doubles Meja Stage-II capacity to 2,400 MW with new JV pact
The agreement with UP's state utility adds a third 800 MW unit, but gives no cost or timeline. A moderate, planned move.
Glance Finance puts 12.8% of its market cap into a single AIF
The nano-cap NBFC is sponsoring a Category II fund with a ₹5 crore commitment, a bet equivalent to a significant slice of its own value.
Bilcare forfeits ₹1.575 cr rather than put more cash into Caprihans
The packaging firm is writing off its upfront subscription payment for subsidiary warrants instead of funding a conversion it can't afford.
Fratelli posts first quarterly operating profit, guides 30% revenue jump for FY27
The wine maker turned EBITDA-positive in Q4, posting its first operating profit in recent quarters. It's now targeting ₹240 cr in revenue for FY27.
Jaipur Metro just gave IL&FS Engineering an order worth 111% of its market cap.
A ₹414 cr sub-contract to build metro stations and a viaduct is the first major order since the company entered resolution in 2018.
Court lifts three-year freeze on Care Ratings' assets
The Madras High Court vacated a Feb. 2023 injunction after Care posted security, ending a constraint on its ability to manage its property.
Sattva Sukun's profit plummets 92% after rights issue
Annual net profit fell to ₹21.17 lakhs from ₹248.94 lakhs. The company confirms the ₹19.16 crore raised in its rights issue was spent as planned.
Sattva Sukun reports FY26; rights-issue proceeds spent as planned
Audited results for Q4 and FY26 are in. The auditor gave a clean opinion, and the company confirmed it used its ₹19.16 crore rights-issue money with no deviations.
Sattva Sukun files routine FY26 results and rights-issue utilisation report
The board signed off on audited results and a statement confirming rights-issue proceeds were spent as planned. No surprises.
Axiscades deferred ₹142 cr in Q4; FY27 guidance holds at ₹1,377 cr
Supply-chain snags on defence programs pushed revenue into the new year. Management says the deferred ₹142 crore will show up in H1 FY27.
Apollo Ingredients sets an RPT limit equal to its entire revenue
The board cleared a ₹5 crore related-party transaction limit with an associate. That ceiling matches Apollo Ingredients' total income for FY26.